OREGON HEALTH AUTHORITY

DRUG USE REVIEW BOARD/PHARMACY AND THERAPEUTICS COMMITTEE (P&T)

High Cost and Marginal Benefit (HCMB) Therapies Policy

GOAL:
To collaborate with and assist the Health Evidence Review Commission (HERC) to evaluate available evidence with a transparent process to encourage safe and financially sustainable policies that maximize access to high value medications for patients served by the Oregon Health Plan (OHP).

PROCEDURES:
1. The P&T thoroughly evaluates drugs for evidence of clinical effectiveness and safety as defined by the P&T Operating Procedures for PDL decision-making.
   a. The reviews are made in public with opportunity and consideration of public comment and input.
2. After the clinical review, cost is considered in executive session. After the executive session, recommendations to be made to the OHA are made with a public vote.
3. The P&T may elect to recommend the HERC consider adding drugs that exhibit one or more of the following characteristics to the new Lines on the Prioritized List:
   a. Marginal clinical benefit
   b. No clinically important benefit
   c. Harms that outweigh benefits
   d. Very high cost in which the benefit does not justify the cost
   e. Significantly greater cost compared to alternate therapies when both have similar benefit
   f. Significant budget impact that could affect the overall Prioritized List funding level